Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Smith & Nephew Plc
  6. News
  7. Summary
    SN.   GB0009223206

SMITH & NEPHEW PLC

(SN.)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Emerging markets to fuel Smith & Nephew revenue growth in 2019

02/07/2019 | 04:57am EDT

(Reuters) - British medical products maker Smith & Nephew forecast full-year revenue growth in line with analysts' expectations on Thursday, as it looks to grow in emerging markets and expand its product line-up.

The company has been under pressure to improve margins and find new sources of growth as it competes with bigger rivals such as Stryker Corp, Zimmer Biomet Holdings and Johnson & Johnson.

The medical technology firm, which rearranged its commercial network in November to boost sales, forecast 2019 profit margins between 22.8 percent and 23.2 percent and revenue growth between 2.5 percent and 3.5 percent, largely in line with estimates.

Smith & Nephew's established markets, including the United States from where the company gets about half of its revenue from, had returned to growth following a tough start to 2018, but have now slowed as the market saturates. Emerging markets, especially China, however, are growing.

Revenue edged up 1.3 percent to $1.29 billion (999.61 million pounds) from a year earlier, just short of average analyst forecast of $1.30 billion, according to a company-provided consensus, as growth in established markets slowed and it was hurt by a stronger dollar.

Smith & Nephew's operating profit for fiscal 2018 fell 7.6 percent to $863 million from a year earlier. Its adjusted earnings of 100.9 cents per share beat expectations of 95 cents.

The company also said that UK's decision to leave the European Union will not have any "significant impact" on its long-term ability to conduct business in the region.

(This story corrects adjusted EPS in sixth paragraph and clarifies it beat estimates, not missed).

(Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham and Arun Koyyur)


ę Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
BYD COMPANY LIMITED 8.34% 280.6 End-of-day quote.38.09%
EURO / US DOLLAR (EUR/USD) -0.02% 1.1835 Delayed Quote.-2.82%
JOHNSON & JOHNSON -0.59% 173.36 Delayed Quote.10.15%
LETS HOLDINGS GROUP CO., LTD. -2.50% 6.23 End-of-day quote.-19.92%
LOOK HOLDINGS INCORPORATED -2.23% 1360 End-of-day quote.42.11%
SMITH & NEPHEW PLC -0.46% 1403 Delayed Quote.-7.32%
All news about SMITH & NEPHEW PLC
08/04SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exc..
PU
08/02European ADRs Move Higher in Monday Trading
MT
08/02SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exc..
PU
07/29European ADRs Move Higher in Thursday Trading
MT
07/29SMITH & NEPHEW : Keeps FY21 Outlook As Profit, Revenue Climb In H1
MT
07/29SMITH & NEPHEW : revenues grew by almost 50 per cent since last quarter
AQ
07/29Smith & Nephew Swung to 1st Half Pretax Profit; Backs Guidance
DJ
07/29SMITH & NEPHEW : +Nephew Second Quarter and First Half 2021 Results
PU
07/29Smith & Nephew plc Reports Earnings Results for the Half Year Ended July 3, 2..
CI
07/29Smith & Nephew plc Announces Interim Dividend, Payable on October 27, 2021
CI
More news
Financials (USD)
Sales 2021 5 388 M - -
Net income 2021 479 M - -
Net Debt 2021 1 866 M - -
P/E ratio 2021 34,9x
Yield 2021 1,84%
Capitalization 17 065 M 17 082 M -
EV / Sales 2021 3,51x
EV / Sales 2022 3,25x
Nbr of Employees 18 000
Free-Float 99,1%
Chart SMITH & NEPHEW PLC
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 19,44 $
Average target price 23,05 $
Spread / Average Target 18,6%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Roberto Quarta Chairman
Vasant Padmanabhan President-Research & Development
Mark Gladwell President-Global Operations & Business Services
Sector and Competitors